BioTheryX secures $92M to advance protein degradation oncology pipeline

By The Science Advisory Board staff writers

BioTheryX announced it has secured $92 million in series E financing to advance multiple molecular glues, PHM-based proteolysis-targeting chimeras (PROTACs), and monovalent degraders toward clinical development.

The funding was led by Farallon Capital Management. The company reported it plans to bring its first molecular glue program, BTX-1188, into the clinic by the end of 2021, and expand its platform of molecular glues, PROTACs, and monovalent degraders.

In addition, the company plans to advance the clinical development of its lead multikinase inhibitor, BTX-A51, for the treatment of acute myeloid leukemia, myelodysplastic syndromes, and solid tumors.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?